Nobilis IB Primo QX

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

virus ptica živčanog infektivnog bronhitisa, soj D388

Available from:

Intervet International B.V.

ATC code:

QI01AD07

INN (International Name):

avian infectious bronchitis virus strain D388

Therapeutic group:

Piletina

Therapeutic area:

Live viral vaccines, Domestic fowl

Therapeutic indications:

Za aktivnu imunizaciju pilića kako bi se smanjili respiratorni znakovi infektivnog bronhitisa ptičjega uzrokovan QX-sličnim varijantama infektivnog bronhitisa.

Product summary:

Revision: 5

Authorization status:

odobren

Authorization date:

2014-09-04

Patient Information leaflet

                                19
B. UPUTA O VMP
20
UPUTA O VMP:
NOBILIS IB PRIMO QX, LIOFILIZAT I OTAPALO ZA OKULONAZALNU SUSPENZIJU,
ZA PILIĆE
NOBILIS IB PRIMO QX
l
IOFILIZAT ZA OKULONAZALNU SUSPENZIJU ZA PILIĆE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za
puštanje serije u promet:
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Nizozemska
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Nobilis IB Primo QX, liofilizat i otapalo za okulonazalnu suspenziju,
za piliće
Nobilis IB Primo QX, liofilizat i za okulonazalnu suspenziju, za
piliće
3.
NAVOĐENJE DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
Svaka doza rekonstituiranog cjepiva sadrži:
Živi atenuirani virus zaraznog bronhitisa kokoši; soj D388: 10
4,0
- 10
5,5
EID
50
1
1
50% infektivna doza za jaja
Liofilizat: krem boje, pretežno okruglog oblika.
Otapalo (okulo/nazalno otapalo): plava otopina.
4.
INDIKACIJA(E)
Za aktivnu imunizaciju pilića s ciljem smanjivanja respiratornih
znakova zaraznog bronhitisa kokoši
uzrokovanog varijantama sličnim QX virusu zaraznog bronhitisa (IBV).
Početak imunosti: 3 tjedna.
Trajanje imunosti: 8 tjedana.
5.
KONTRAINDIKACIJE
Nema.
6.
NUSPOJAVE
Vrlo rijetko može se pojaviti blaga, prolazna respiratorna reakcija
(uključujući nazalne eksudate)
tijekom najmanje 10 dana nakon cijepljenja.
Učestalost nuspojava je određena sukladno sljedećim pravilima:
- vrlo česte (više od 1 na 10 tretiranih životinja pokazuju
nuspojavu(e))
- česte (više od 1 ali manje od 10 životinja na 100 tretiranih
životinja)
- manje česte (više od 1 ali manje od 10 životinja na 1.000
tretiranih životinja)
- rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih
životinja)
- vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja,
uključujući izolirane slučajeve).>
21
Ako zamijetite bilo koju nuspojavu, čak i one koje nisu navedene u
ovoj uputi o VMP i
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Nobilis IB Primo QX, liofilizat i otapalo za okulonazalnu suspenziju,
za piliće
Nobilis IB Primo QX, liofilizat za okulonazalnu suspenziju, za piliće
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka doza rekonstituiranog cjepiva sadrži:
DJELATNA TVAR:
Živi atenuirani virus zaraznog bronhitisa kokoši; soj D388: 10
4,0
- 10
5,5
EID
50
1
1
50% infektivna doza za jaja
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Liofilizat i otapalo za suspenziju za okulonazalnu suspenziju
Liofilizat za okulonazalnu suspenziju
Liofilizat: krem boje, pretežno okruglog oblika.
Otapalo (okulo/nazalno otapalo): plava otopina.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Pilići.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za aktivnu imunizaciju pilića s ciljem smanjivanja respiratornih
znakova zaraznog bronhitisa kokoši
uzrokovanog varijantama sličnim QX virusu zaraznog bronhitisa (IBV).
Početak imunosti: 3 tjedna.
Trajanje imunosti: 8 tjedana.
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA
Cijepiti samo zdrave životinje.
Cjepni virus može se širiti kontaktom ptica tijekom minimalno 20
dana nakon cijepljenja te treba
paziti da se cijepljeni pilići odvoje od necijepljenih. Moraju se
poduzeti mjere predostrožnosti zbog
sprječavanja širenja virusa na divlje životinje. Nakon svakog
proizvodnog ciklusa, prostorije se moraju
očistiti i dezinficirati.
Ovo cjepivo treba se upotrebljavati samo nakon utvrđivanja
epidemiološke važnosti varijantnog soja
virusa sličnog QX soju virusa zaraznog bronhitisa. Važno je izbjeći
uvođenje D388 vakcinalnog virusa
zaraznog bronhitisa u prostore u kojima divlji soj virusa nije
prisutan. IB D388 vakcina treba se
primjenjivati u valionicama kod pilića starih 1 dan ili starijih ako
se primjenjuje odgovarajuća kontrola
3
kako bi se izbjeglo širenje vakcinalnog virusa na ptice koje će se
premjestiti u jata koja nisu izložena
QX soju virusa zaraznog bronhi
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-04-2021
Public Assessment Report Public Assessment Report Bulgarian 28-01-2021
Patient Information leaflet Patient Information leaflet Spanish 26-04-2021
Public Assessment Report Public Assessment Report Spanish 28-01-2021
Patient Information leaflet Patient Information leaflet Czech 26-04-2021
Public Assessment Report Public Assessment Report Czech 04-11-2014
Patient Information leaflet Patient Information leaflet Danish 26-04-2021
Public Assessment Report Public Assessment Report Danish 28-01-2021
Patient Information leaflet Patient Information leaflet German 26-04-2021
Public Assessment Report Public Assessment Report German 28-01-2021
Patient Information leaflet Patient Information leaflet Estonian 26-04-2021
Public Assessment Report Public Assessment Report Estonian 28-01-2021
Patient Information leaflet Patient Information leaflet Greek 26-04-2021
Public Assessment Report Public Assessment Report Greek 28-01-2021
Patient Information leaflet Patient Information leaflet English 26-04-2021
Public Assessment Report Public Assessment Report English 28-01-2021
Patient Information leaflet Patient Information leaflet French 26-04-2021
Public Assessment Report Public Assessment Report French 28-01-2021
Patient Information leaflet Patient Information leaflet Italian 26-04-2021
Public Assessment Report Public Assessment Report Italian 28-01-2021
Patient Information leaflet Patient Information leaflet Latvian 26-04-2021
Public Assessment Report Public Assessment Report Latvian 28-01-2021
Patient Information leaflet Patient Information leaflet Lithuanian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-04-2021
Public Assessment Report Public Assessment Report Lithuanian 28-01-2021
Patient Information leaflet Patient Information leaflet Hungarian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 26-04-2021
Public Assessment Report Public Assessment Report Hungarian 28-01-2021
Patient Information leaflet Patient Information leaflet Maltese 26-04-2021
Public Assessment Report Public Assessment Report Maltese 28-01-2021
Patient Information leaflet Patient Information leaflet Dutch 26-04-2021
Public Assessment Report Public Assessment Report Dutch 28-01-2021
Patient Information leaflet Patient Information leaflet Polish 26-04-2021
Public Assessment Report Public Assessment Report Polish 28-01-2021
Patient Information leaflet Patient Information leaflet Portuguese 26-04-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 26-04-2021
Public Assessment Report Public Assessment Report Portuguese 28-01-2021
Patient Information leaflet Patient Information leaflet Romanian 26-04-2021
Public Assessment Report Public Assessment Report Romanian 28-01-2021
Patient Information leaflet Patient Information leaflet Slovak 26-04-2021
Public Assessment Report Public Assessment Report Slovak 28-01-2021
Patient Information leaflet Patient Information leaflet Slovenian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 26-04-2021
Public Assessment Report Public Assessment Report Slovenian 28-01-2021
Patient Information leaflet Patient Information leaflet Finnish 26-04-2021
Public Assessment Report Public Assessment Report Finnish 28-01-2021
Patient Information leaflet Patient Information leaflet Swedish 26-04-2021
Public Assessment Report Public Assessment Report Swedish 28-01-2021
Patient Information leaflet Patient Information leaflet Norwegian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 26-04-2021
Patient Information leaflet Patient Information leaflet Icelandic 26-04-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 26-04-2021